Marker Therapeutics Aktie

Marker Therapeutics ab 0 Euro bei Finanzen invest ordern (zzgl. Spreads)

WKN DE: A2N7XT / ISIN: US57055L1070

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
22.09.2026 18:45:45

Marker Highlights Expanded Manufacturing Support For MT-601

(RTTNews) - Marker Therapeutics, Inc. (MRKR), announced on Tuesday that its lead program MT-601 (neldaleucel) will benefit from expanded manufacturing capabilities following the formation of Kincellis Advanced Therapies, a U.S. cell therapy contract development and manufacturing organization.

Kincellis was created through the combination of Cellipont Bioservices and Kincell Bio, announced on September 17, 2026, and now operates about 140,000 square feet of infrastructure and 16 GMP manufacturing suites across three U.S. sites. Marker had previously selected Cellipont as its manufacturing partner for MT-601.

MT-601 is under investigation in the Phase 1 APOLLO study in lymphoma patients who relapsed after anti-CD19 CAR-T therapy or are not candidates for it. Marker has reported a 66% objective response rate among 12 patients, with half achieving complete remission.

On the Nasdaq, shares of Marker Therapeutics are currently gaining 0.04 percent, changing hands at $1.2005.

Nachrichten zu Marker Therapeutics Inc Registered Shs (Old)

mehr Nachrichten
Keine Nachrichten verfügbar.

Analysen zu Marker Therapeutics Inc Registered Shs (Old)

mehr Analysen
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!